Incyte (INCY) to Halt Ruxolitinib + Capecitabine Phase 3 in Advanced or Metastatic Pancreatic Cancer
Tweet Send to a Friend
Incyte Corporation (Nasdaq: INCY) announced its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
